<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib58">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Stroud</surname>
    <given-names>CR</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hegde</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Cherry</surname>
    <given-names>C</given-names>
   </name>
   <etal>et al.</etal>
  </person-group>
  <article-title>Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade</article-title>. 
  <source>J Oncol Pharm Pract</source>. 
  <year>2019</year>;
  <volume>25</volume>:
  <fpage>551</fpage>â€“
  <lpage>7</lpage>.
  <pub-id pub-id-type="pmid">29207939</pub-id>
 </mixed-citation>
</ref>
